KYG8807B1068
KYG8807B1068
Theravance Biopharma, Inc.
Loading chart...
Financials
Trends
* Timeframes marked with (Est.) are analyst estimates based on consensus data.
Details
| Breakdown | 2025 | 2024 | Change % |
|---|---|---|---|
| Total Revenue | 107.464.000 | 64.381.000 | 66.9% |
| Cost of Revenue | -- | -- | -- |
| Gross Profit | -- | -- | -- |
| 111.066.000 | 106.817.000 | 4.0% | |
| Operating Income | -3.602.000 | -42.436.000 | 91.5% |
| Pretax Income | 129.247.000 | -44.614.000 | 389.7% |
| Net Income Common Stockholders | 105.895.000 | -56.418.000 | 287.7% |
| -- | -- | -- | |
| -- | -- | -- |